Genetic data help detect preclinical Alzheimer’s disease and target individuals for clinical trials, making genetic research engagement critical for continued advancement in dementia prevention and treatment.
Objective:
To understand what individual and institutional factors may relate to provision of genetic samples within the Alzheimer’s Disease Centers.
Methods:
Data from the National Alzheimer’s Coordinating Center Uniform Data Set (2009–2016) were obtained along with genetic sample availability. Logistic regression was used to assess independent contributions of demographic and clinical characteristics to the probability of sample provision. Sites contributing data completed a brief survey exploring regulatory and scientific issues related to genetic research engagement.
Results:
Just over half (52.1%) of the 27,519 unique participants had genetic data available. Female sex, white race, non-Hispanic ethnicity, normal cognition, and greater than 5 years of follow-up were associated with greater probability of availability. Sites identified refusals as the most frequent barrier to sample provision, followed by staff availability.
Conclusion:
These results highlight the importance of strategies to promote minority engagement and encourage earlier genetic research participation.
BeskowLM, DeanE (2008) Informed consent for biorepositories: Assessing prospective participants’ understanding and opinions. Cancer Epidemiol Biomarkers Prev17, 1440–1451.
4.
BrothersKB, MorrisonDR, ClaytonEW (2011) Two large-scale surveys on community attitudes toward an opt-out biobank. Am J Med Genet A155a, 2982–2990.
5.
ChenDT, RosensteinDL, MuthappanP, HilsenbeckSG, MillerFG, EmanuelEJ, WendlerD (2005) Research with stored biological samples: What do research participants want?Arch Intern Med165, 652–655.
6.
AkinleyeI, RobertsJS, RoyalCD, LinnenbringerE, ObisesanTO, FasayeGA, GreenRC (2011) Differences between African American and White research volunteers in their attitudes, beliefs and knowledge regarding genetic testing for Alzheimer’s disease. J Genet Couns20, 650–659.
7.
HippsYG, RobertsJS, FarrerLA, GreenRC (2003) Differences between African Americans and Whites in their attitudes toward genetic testing for Alzheimer’s disease. Genet Test7, 39–44.
8.
Bussey-JonesJ, GarrettJ, HendersonG, MoloneyM, BlumenthalC, Corbie-SmithG (2010) The role of race and trust in tissue/blood donation for genetic research. Genet Med12, 116–121.
9.
BoiseL, HintonL, RosenHJ, RuhlM (2016) Will my soul go to heaven if they take my brain? Beliefs and worries about brain donation among four ethnic groups. Gerontologist57, 719–734.
10.
IghodaroET, NelsonPT, KukullWA, SchmittFA, AbnerEL, Caban-HoltA, BardachSH, HordDC, GloverCM, JichaGA (2017) Challenges and considerations related to studying dementia in Blacks/African Americans. J Alzheimers Dis60, 1–10.
11.
RobertsJS, CupplesLA, RelkinNR, WhitehousePJ, GreenRC, REVEAL (Risk Evaluation and Education for Alzheimer’s Disease) Study Group (2005) Genetic risk assessment for adult children of people with Alzheimer’s disease: The Risk Evaluation and Education for Alzheimer’s Disease (REVEAL) study. J Geriatr Psychiatry Neurol18, 250–255.
12.
GoodingHC, LinnenbringerEL, BurackJ, RobertsJS, GreenRC, BieseckerBB (2006) Genetic susceptibility testing for Alzheimer disease: Motivation to obtain information and control as precursors to coping with increased risk. Patient Educ Couns64, 259–267.
13.
HurleyAC, HarveyFR, RobertsJS, Wilson-ChaseC, LloydS, PrestJ, LockM, HorvathKJ, GreenRC (2005) Genetic susceptibility for Alzheimer’s disease: Why did adult offspring seek testing?Am J Alzheimers Dis Other Demen20, 374–381.
14.
RobertsJS, BarberM, BrownTM, CupplesLA, FarrerLA, LaRusseSA, PostSG, QuaidKA, RavdinLD, RelkinNR, SadovnickAD, WhitehousePJ, WoodardJL, GreenRC (2004) Who seeks genetic susceptibility testing for Alzheimer’s disease? Findings from a multisite, randomized clinical trial. Genet Med6, 197–203.
15.
RobertsJS, ChristensenKD, GreenRC (2011) Using Alzheimer’s disease as a model for genetic risk disclosure: Implications for personal genomics. Clin Genet80, 407–414.
16.
GreenMJ, BieseckerBB, McInerneyAM, MaugerD, FostN (2001) An interactive computer program can effectively educate patients about genetic testing for breast cancer susceptibility. Am J Med Genet103, 16–23.
17.
GreenRC, ChristensenKD, CupplesLA, RelkinNR, WhitehousePJ, RoyalCD, ObisesanTO, Cook-DeeganR, LinnenbringerE, ButsonMB, FasayeGA, LevinsonE, RobertsJS, REVEAL Study Group (2015) A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer’s disease. Alzheimers Dement11, 1222–1230.
18.
LernerB, RobertsJS, ShwartzM, RoterDL, GreenRC, ClarkJA (2014) Distinct communication patterns during genetic counseling for late-onset Alzheimer’s risk assessment. Patient Educ Couns94, 170–179.
19.
CassidyMR, RobertsJS, BirdTD, SteinbartEJ, CupplesLA, ChenCA, LinnenbringerE, GreenRC (2008) Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer’s disease. Alzheimers Dement4, 406–413.
20.
ChaoS, RobertsJS, MarteauTM, SillimanR, CupplesLA, GreenRC (2008) Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study. Alzheimer Dis Assoc Disord22, 94–97.
21.
FanshaweTR, PrevostAT, RobertsJS, GreenRC, ArmstrongD, MarteauTM (2008) Explaining behavior change after genetic testing: The problem of collinearity between test results and risk estimates. Genet Test12, 381–386.
22.
LinnenbringerE, RobertsJS, HirakiS, CupplesLA, GreenRC (2010) “I know what you told me, but this is what I think:” Perceived risk of Alzheimer disease among individuals who accurately recall their genetics-based risk estimate. Genet Med12, 219–227.
23.
MarteauTM, RobertsS, LaRusseS, GreenRC (2005) Predictive genetic testing for Alzheimer’s disease: Impact upon risk perception. Risk Anal25, 397–404.
24.
OstergrenJE, GornickMC, CarereDA, KaliaSS, UhlmannWR, RuffinMT, MountainJL, GreenRC, RobertsJS, PGen Study Group (2015) How well do customers of direct-to-consumer personal genomic testing services comprehend genetic test results? Findings from the impact of personal genomics study. Public Health Genomics18, 216–224.
25.
TaylorDHJr, Cook-DeeganRM, HirakiS, RobertsJS, BlazerDG, GreenRC (2010) Genetic testing for Alzheimer’s and long-term care insurance. Health Aff (Millwood)29, 102–108.
26.
TamborES, BernhardtBA, ChaseGA, FadenRR, GellerG, HofmanKJ, HoltzmanNA (1994) Offering cystic fibrosis carrier screening to an HMO population: Factors associated with utilization. Am J Hum Genet55, 626–637.
27.
KhachaturianZS (2006) Diagnosis of Alzheimer’s disease: Two-decades of progress. J Alzheimers Dis9, 409–415.
28.
MorrisJC, WeintraubS, ChuiHC, CummingsJ, DecarliC, FerrisS, FosterNL, GalaskoD, Graff-RadfordN, PeskindER, BeeklyD, RamosEM, KukullWA (2006) The Uniform Data Set (UDS): Clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord20, 210–216.
BonevskiB, RandellM, PaulC, ChapmanK, TwymanL, BryantJ, BrozekI, HughesC (2014) Reaching the hard-to-reach: A systematic review of strategies for improving health and medical research with socially disadvantaged groups. BMC Med Res Methodol14, 42.
31.
GeorgeS, DuranN, NorrisK (2014) A systematic review of barriers and facilitators to minority research participation among African Americans, Latinos, Asian Americans, and Pacific Islanders. Am J Public Health104, e16–e31.
32.
KraftSA, ChoMK, GillespieK, HalleyM, VarsavaN, OrmondKE, LuftHS, WilfondBS, Soo-Jin LeeS (2018) Beyond consent: Building trusting relationships with diverse populations in precision medicine research. Am J Bioeth18, 3–20.
33.
ChristensenKD, RobertsJS, Zikmund-FisherBJ, KardiaSL, McBrideCM, LinnenbringerE, GreenRC, REVEAL Study Group (2015) Associations between self-referral and health behavior responses to genetic risk information. Genome Med7, 10.
34.
SteenlandK, GoldsteinFC, LeveyA, WhartonW (2016) A meta-analysis of Alzheimer’s disease incidence and prevalence comparing African-Americans and Caucasians. J Alzheimers Dis50, 71–76.
35.
McDonoughIM (2017) Beta-amyloid and cortical thickness reveal racial disparities in preclinical Alzheimer’s disease. Neuroimage Clin16, 659–667.
36.
Lopez LopezC, CaputoA, LiuF, RiviereME, Rouzade-DominguezML, ThomasRG, LangbaumJB, LenzR, ReimanEM, GrafA, TariotPN (2017) The Alzheimer’s Prevention Initiative Generation Program: Evaluating CNP520 efficacy in the prevention of Alzheimer’s disease. J Prev Alzheimers Dis4, 242–246.
